Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...

The FDA meeting de-risked Annamycin's development for AML treatment, allowing higher dosing in the US. The MIRACLE Phase 3 trial has an adaptive design with a primary endpoint of complete remission.